Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Hutchmed (China)
HCM
5
Lantheus
LNTH
US Stock MarketDetailed Quotes
CERS Cerus
- 1.340
- -0.010-0.74%
Close Apr 28 16:00 ET
- 1.390
- +0.050+3.73%
Post 16:35 ET
256.16MMarket Cap-12.18P/E (TTM)
1.365High1.300Low782.00KVolume1.350Open1.350Pre Close1.04MTurnover0.48%Turnover RatioLossP/E (Static)191.16MShares2.54052wk High4.56P/B219.52MFloat Cap1.12052wk Low--Dividend TTM163.82MShs Float81.875Historical High--Div YieldTTM4.82%Amplitude0.550Historical Low1.333Avg Price1Lot Size
About Cerus Company
Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The firm produces blood system for platelets and plasma. It operates through Blood Safety segment. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.
Company Profile
SymbolCERS
Company NameCerus
Listing DateJan 31, 1997
Issue Price12.00
Founded1991
CEOMr. William M. Greenman
MarketNASDAQ
Employees281
Fiscal Year Ends12-31
Address1220 Concord Avenue,Suite 600
CityConcord
ProvinceCalifornia
CountryUnited States of America
Zip Code94520
Phone1-925-288-6000
Websitehttp://www.cerus.com
Company Executives
- Name
- Position
- Salary
- William M. Greenman
- Director, President and Chief Executive Officer
- 2.98M
- Chrystal Jensen
- Chief Legal Officer and General Counsel
- 1.10M
- Vivek K. Jayaraman
- Chief Operating Officer
- 1.48M
- Richard J. Benjamin
- Chief Medical Officer
- 1.13M
- Kevin D. Green
- Vice President, Finance, Chief Financial Officer and Principal Accounting Officer
- 1.27M
- Daniel N. Swisher,Jr
- Chairman of the Board
- 174.60K
- Gail Gaumer Schulze
- Independent Director
- 141.60K
- Jami Dover Nachtsheim
- Independent Director
- 130.60K
- Ann Lucena
- Independent Director
- 146.60K
- Timothy L. Moore
- Independent Director
- 133.60K
- Eric H. Bjerkholt, M.B.A.
- Independent Director
- 130.35K
- Dean Gregory
- Independent Director
- 132.00K
- Dr. Hua Shan, M.D.,PhD
- Independent Director
- 126.04K
- Dr. Frank R. Witney,, PhD
- Independent Director
- 141.60K
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
